Clinical Trial Update: Vitamin D and Omega-3 Inhibit Metabolic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial update suggests Vitamin D and Omega-3 may inhibit metabolic syndrome components. The results come from a completed Phase 3 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Hypertension
• Metabolic Syndrome
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Omega-3 fatty acids (omega-3 fatty acids)
• Vitamin D (Cholecalciferol)

Snippet

Sponsor: University of Guelph | Conditions: Type 2 Diabetes Mellitus, Hypertension | Phase 3 | Status: COMPLETED